Clinical Trials Logo
  1. Home
  2. Radiotherapy
  3. NCT04365049

Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma

PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy Versus Nab-Paclitaxel and Gemcitabine Alone for Locally Advanced Pancreatic Adenocarcinoma

Clinical Trial Summary

The study is a prospective and observational cohort study. The purpose is to to investigate the safety and efficacy of nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma (PDAC)

Clinical Trial Description

We will prospectively collect 100 patients who receive nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy or nab-paclitaxel and gemcitabine alone. Data will be stored in a private database. The process of data collection will be supervised and regular data examination will be performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04365049
Study type Observational [Patient Registry]
Source Sun Yat-sen University
Contact Ming Kuang, PhD
Phone 008687755766
Email kuangm@mail.sysu.edu.cn
Status Recruiting
Phase
Start date April 1, 2020
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Recruiting NCT05262855 - Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma Phase 2
Recruiting NCT04700488 - Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC) N/A
Not yet recruiting NCT05947825 - Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients Phase 2
Recruiting NCT06151223 - A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Recruiting NCT05845801 - Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
Recruiting NCT05853198 - Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability N/A
Recruiting NCT05669287 - Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics N/A
Recruiting NCT05727020 - Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Recruiting NCT05218889 - Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05132244 - Monitoring and Managing Glucose Levels in People With Pancreatic Cancer N/A